Abiopharma

New Form 6-K - Haleon plc Filed: 2025-06-16 AccNo: 0001654954-25-006949 Size: 34 KB

General Announcement: Press Release - BJCG Subsidiary and KLWC Elevate Malaysias Health & Wellness Landscape

New Form 8-K - Jasper Therapeutics, Inc. Filed: 2025-06-16 AccNo: 0001213900-25-054465 Size: 19 MB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

New Form DEFA14A - SpringWorks Therapeutics, Inc. Filed: 2025-06-16 AccNo: 0001104659-25-059584 Size: 27 KB

New Form 6-K - GSK plc Filed: 2025-06-16 AccNo: 0001654954-25-006946 Size: 2 MB

New Form 8-K - SpringWorks Therapeutics, Inc. Filed: 2025-06-16 AccNo: 0001104659-25-059579 Size: 200 KB Item 8.01: Other Events

New Form EFFECT - Imunon, Inc. Filed: 2025-06-13 AccNo: 9999999995-25-001928 Size: 2 KB

Disclosure of Interest/ Changes in Interest of Substantial Shareholder(s)/ Unitholder(s): Becoming a Substantial Shareholder - Wong Kong Leong

General Announcement: CHANGES IN SUBSTANTIAL SHAREHOLDERS INTEREST PURSUANT TO SECTION 138 OF THE COMPANIES ACT, 2016

Disclosure of Interest/ Changes in Interest of Substantial Shareholder(s)/ Unitholder(s): Cessation of Substantial Shareholder - Ong Choon Yi

UroGen Pharma Ltd. Class Action: The Gross Law Firm Reminds UroGen Pharma Ltd. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 28, 2025 - URGN

General Announcement: CHANGES IN SUBSTANTIAL SHAREHOLDERS INTEREST PURSUANT TO SECTION 138 OF THE COMPANIES ACT 2016

FDA approve CLOZAPINE

FDA approve EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

FDA approve LEVOCETIRIZINE DIHYDROCHLORIDE